As a proof of principle for the therapeutic implications of our approach, treatment of the cells with the clinical grade menin inhibitor (revumenib, previously known as SNDX-5613), which is currently producing promising results in a clinical trial in KMT2A-mutated and NPM1-mutated AML (AUGMENT-01; ClinicalTrials.gov registration: NCT04065399) (ref. 34), recapitulated the Men1 and Kmt2a knockout single-cell phenotype to induce a dose-dependent granulocytic differentiation and decrease in proliferation (Fig. 5g,h and Supplementary Fig. 7). Here, MEN1 is linked to acute myeloid leukemia.